Illimis Therapeutics key facts
- Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases.
- It has raised $64.3M; the latest was Early Stage VC ($42.0M) in Jul 2025.
- Notable investors include Tech Incubator Program for Startup, Korea Development Bank, IMM Investment, Hana Ventures, STIC Ventures — 27 tracked in total.
- Status: Privately Held (backing).
Who backs Illimis Therapeutics
27+- ·The complete investor list: 27 names
- ·Watch Illimis Therapeutics: the Monday email on marks, rounds and moves
Illimis Therapeutics funding rounds
No funding rounds for Illimis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Illimis Therapeutics investors
27 investors are on record for Illimis Therapeutics, including Tech Incubator Program for Startup, Korea Development Bank, IMM Investment and Hana Ventures. By type, the record holds 8 venture capital firms and 1 hedge fund.
About Illimis Therapeutics
Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. The company's platform leverages proprietary protein engineering and molecular design techniques, enabling the biopharmaceutical companies to increase drug candidates with target specificity and improved stability.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2021
- Employees
- 40
- Website
- illimistx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Illimis Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.